{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:12:20Z","timestamp":1789391540666,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI47367"],"award-info":[{"award-number":["R37AI47367"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI096882"],"award-info":[{"award-number":["R01AI096882"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI131313"],"award-info":[{"award-number":["U01AI131313"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.coviro.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T01:15:58Z","timestamp":1495674958000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Designing an HCV vaccine: a unique convergence of prevention and therapy?"],"prefix":"10.1016","volume":"23","author":[{"given":"Christopher M","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2017.03.014_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.coviro.2017.03.014_bib0010","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2006.12.008","article-title":"Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo","volume":"132","author":"von Hahn","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI78794","article-title":"Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance","volume":"125","author":"Bailey","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.coviro.2017.03.014_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00430-014-0372-z","article-title":"Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections","volume":"204","author":"Timm","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0025","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J. Hepatol."},{"issue":"Suppl 1","key":"10.1016\/j.coviro.2017.03.014_bib0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/liv.12063","article-title":"Best strategies for global HCV eradication","volume":"33","author":"Hagan","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.coviro.2017.03.014_bib0035","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.15585\/mmwr.mm6541a2","article-title":"National progress toward hepatitis C elimination\u2014Georgia, 2015\u20132016","volume":"65","author":"Gvinjilia","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.coviro.2017.03.014_bib0040","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.aad1302","article-title":"Medicine: global control of hepatitis C virus","volume":"349","author":"Cox","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coviro.2017.03.014_sbref0045","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.014_bib0050","doi-asserted-by":"crossref","first-page":"e0156213","DOI":"10.1371\/journal.pone.0156213","article-title":"The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals?","volume":"11","author":"Stone","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2017.03.014_bib0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after Sofosbuvir-based therapies","volume":"64","author":"Sarrazin","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.014_bib0060","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gutjnl-2011-300620","article-title":"T cell responses in hepatitis C: the good, the bad and the unconventional","volume":"61","author":"Klenerman","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2017.03.014_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2014.11.009","article-title":"T cell responses in hepatitis C virus infection: historical overview and goals for future research","volume":"114","author":"Holz","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.coviro.2017.03.014_bib0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.014_bib0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0080","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1053\/j.gastro.2010.05.077","article-title":"Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins","volume":"139","author":"Dahari","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0085","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/JVI.78.3.1575-1581.2004","article-title":"Cross-genotype immunity to hepatitis C virus","volume":"78","author":"Lanford","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0090","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.coviro.2017.03.014_bib0095","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/14760584.2016.1194759","article-title":"Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies","volume":"15","author":"Fauvelle","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.coviro.2017.03.014_bib0100","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.03574-13","article-title":"Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses","volume":"88","author":"Chmielewska","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0105","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.93.26.15394","article-title":"Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein","volume":"93","author":"Farci","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.03.014_bib0110","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees","volume":"8","author":"Morin","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.coviro.2017.03.014_bib0115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature10168","article-title":"A genetically humanized mouse model for hepatitis C virus infection","volume":"474","author":"Dorner","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2017.03.014_bib0120","doi-asserted-by":"crossref","first-page":"9128","DOI":"10.1128\/JVI.01194-15","article-title":"Immunoglobulin with high-titer in vitro cross-neutralizing hepatitis C virus antibodies passively protects chimpanzees from homologous, but not heterologous, challenge","volume":"89","author":"Bukh","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0125","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0130","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.03.014_bib0135","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0140","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus","volume":"136","author":"Dowd","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0145","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/infdis\/173.4.822","article-title":"Effect of immune globulin on the prevention of experimental hepatitis C virus infection","volume":"173","author":"Krawczynski","year":"1996","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.014_bib0150","doi-asserted-by":"crossref","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.coviro.2017.03.014_bib0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.coviro.2017.03.014_bib0160","doi-asserted-by":"crossref","first-page":"e59776","DOI":"10.1371\/journal.pone.0059776","article-title":"A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans","volume":"8","author":"Law","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2017.03.014_bib0165","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2017.03.014_sbref0170","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02309-16","article-title":"Computational prediction of the heterodimeric and higher order structure of gpE1\/gpE2 envelope glycoproteins encoded by the hepatitis C virus (HCV)","volume":"91","author":"Freedman","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0175","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/acsinfecdis.6b00110","article-title":"Structure and function of the hepatitis C virus envelope glycoproteins E1 and E2: antiviral and vaccine targets","volume":"2","author":"Freedman","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0180","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01552-16","article-title":"Native folding of a recombinant gpE1\/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG","volume":"91","author":"Logan","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0185","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.coviro.2017.03.014_bib0190","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection","volume":"197","author":"Shoukry","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.coviro.2017.03.014_bib0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2249.1997.508-ce1412.x","article-title":"Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up","volume":"110","author":"Christie","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0200","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0205","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1053\/j.gastro.2012.06.005","article-title":"Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus","volume":"143","author":"Park","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.014_sbref0210","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.coviro.2017.03.014_bib0215","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.coviro.2017.03.014_bib0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1084\/jem.20100388","article-title":"Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence","volume":"209","author":"Schulze Zur Wiesch","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.coviro.2017.03.014_bib0225","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0230","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28309","article-title":"Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral","volume":"63","author":"Callendret","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0235","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.28294","article-title":"Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans","volume":"63","author":"Kelly","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0240","article-title":"Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection","volume":"4","author":"Swadling","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.coviro.2017.03.014_sbref0245","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2017.03.014_sbref0250","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","article-title":"Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)","volume":"110","author":"Fuller","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0255","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2017.03.014_sbref0260","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0265","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/infdis\/jiw457","article-title":"Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C","volume":"214","author":"Hengst","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.coviro.2017.03.014_bib0270","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/eji.201646447","article-title":"Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy","volume":"46","author":"Hengst","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0275","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-specific CD8+ T cell function by interferon-free therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.coviro.2017.03.014_bib0280","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/jvh.12465","article-title":"Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals","volume":"22","author":"Burchill","year":"2015","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.coviro.2017.03.014_sbref0285","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1038\/ncomms15050","article-title":"TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation","volume":"8","author":"Wieland","year":"2017","journal-title":"Nature. Commun."},{"key":"10.1016\/j.coviro.2017.03.014_bib0290","doi-asserted-by":"crossref","first-page":"e0171217","DOI":"10.1371\/journal.pone.0171217","article-title":"Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2017.03.014_sbref0295","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.27278","article-title":"T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee","volume":"60","author":"Callendret","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2017.03.014_bib0300","doi-asserted-by":"crossref","first-page":"1237874","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625717300263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625717300263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T08:58:00Z","timestamp":1535792280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625717300263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":60,"alternative-id":["S1879625717300263"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2017.03.014","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing an HCV vaccine: a unique convergence of prevention and therapy?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}